BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2362273)

  • 1. Conformational restriction of angiotensin II: cyclic analogues having high potency.
    Spear KL; Brown MS; Reinhard EJ; McMahon EG; Olins GM; Palomo MA; Patton DR
    J Med Chem; 1990 Jul; 33(7):1935-40. PubMed ID: 2362273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple binding modes for the receptor-bound conformations of cyclic AII agonists.
    Plucinska K; Kataoka T; Yodo M; Cody WL; He JX; Humblet C; Lu GH; Lunney E; Major TC; Panek RL
    J Med Chem; 1993 Jun; 36(13):1902-13. PubMed ID: 8515427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinyl sulfide cyclized analogues of angiotensin II with high affinity and full agonist activity at the AT(1) receptor.
    Johannesson P; Lindeberg G; Johansson A; Nikiforovich GV; Gogoll A; Synnergren B; Le Grèves M; Nyberg F; Karlén A; Hallberg A
    J Med Chem; 2002 Apr; 45(9):1767-77. PubMed ID: 11960488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topographic probes of angiotensin and receptor: potent angiotensin II agonist containing diphenylalanine and long-acting antagonists containing biphenylalanine and 2-indan amino acid in position 8.
    Hsieh KH; LaHann TR; Speth RC
    J Med Chem; 1989 Apr; 32(4):898-903. PubMed ID: 2704034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of D-amino acid substitution on antagonist activities of angiotensin II analogues.
    Samanen J; Narindray D; Adams W; Cash T; Yellin T; Regoli D
    J Med Chem; 1988 Mar; 31(3):510-6. PubMed ID: 3346871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarmesin is a partial agonist of angiotensin-II receptors in rabbit, but not in rat, aortic rings.
    Criscione L; Thomann H; Whitebread S; de Gasparo M; Kamber B
    Biochem Biophys Res Commun; 1990 Jun; 169(2):636-42. PubMed ID: 2357223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological activities of four angiotensin II receptor ligands with gamma-turn mimetics replacing amino acid residues 3-5.
    Schmidt B; Lindman S; Tong W; Lindeberg G; Gogoll A; Lai Z; Thörnwall M; Synnergren B; Nilsson A; Welch CJ; Sohtell M; Westerlund C; Nyberg F; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):903-19. PubMed ID: 9083479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
    Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
    Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of the N-terminal domain of the type I angiotension II antagonist [Sar1,Ile8]ANG II for receptor blockade.
    Moore GJ; Ganter RC; Goghari MH; Franklin KJ
    Int J Pept Protein Res; 1991 Jul; 38(1):1-7. PubMed ID: 1938100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AT1 receptor characteristics of angiotensin analogue binding in human synovium.
    Walsh DA; Suzuki T; Knock GA; Blake DR; Polak JM; Wharton J
    Br J Pharmacol; 1994 Jun; 112(2):435-42. PubMed ID: 8075862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel synthesis of cyclic amide-linked analogues of angiotensins II and III.
    Matsoukas JM; Hondrelis J; Agelis G; Barlos K; Gatos D; Ganter R; Moore D; Moore GJ
    J Med Chem; 1994 Sep; 37(18):2958-69. PubMed ID: 8071943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships for the carboxy-terminus truncated analogues of angiotension II, a new class of angiotensin II antagonists.
    Bovy PR; O'Neal JM; Olins GM; Patton DR; McMahon EG; Palomo M; Koepke JP; Salles KS; Trapani AJ; Smits GJ
    J Med Chem; 1990 May; 33(5):1477-82. PubMed ID: 2329570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An investigation of angiotensin II agonist and antagonist analogues with 5,5-dimethylthiazolidine-4-carboxylic acid and other constrained amino acids.
    Samanen J; Cash T; Narindray D; Brandeis E; Adams W; Weideman H; Yellin T; Regoli D
    J Med Chem; 1991 Oct; 34(10):3036-43. PubMed ID: 1920354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of residues 2 (arginine) and 6 (histidine) in high-affinity angiotensin II antagonists.
    Samanen J; Brandeis E; Narindray D; Adams W; Cash T; Yellin T; Regoli D
    J Med Chem; 1988 Apr; 31(4):737-41. PubMed ID: 3351849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of extracellular calcium concentration on angiotensin AT1 receptor-mediated smooth muscle contraction and antagonism in rabbit aorta.
    Liu YJ
    Eur J Pharmacol; 1992 Nov; 223(2-3):205-9. PubMed ID: 1478269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor binding interactions of the angiotensin II antagonist, 125I-[sarcosine1,leucine8]angiotensin II, with mammalian brain and peripheral tissues.
    Bennett JP; Snyder SH
    Eur J Pharmacol; 1980 Oct; 67(1):11-25. PubMed ID: 6252019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent angiotensin II antagonists with non-beta-branched amino acids in position 5.
    Samanen J; Narindray D; Cash T; Brandeis E; Adams W; Yellin T; Eggleston D; DeBrosse C; Regoli D
    J Med Chem; 1989 Feb; 32(2):466-72. PubMed ID: 2913307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications.
    Zhang WJ; Nikiforovich GV; Pérodin J; Richard DE; Escher E; Marshall GR
    J Med Chem; 1996 Jul; 39(14):2738-44. PubMed ID: 8709104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II.
    Matsoukas JM; Polevaya L; Ancans J; Mavromoustakos T; Kolocouris A; Roumelioti P; Vlahakos DV; Yamdagni R; Wu Q; Moore GJ
    Bioorg Med Chem; 2000 Jan; 8(1):1-10. PubMed ID: 10968258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.
    Virone-Oddos A; Desangle V; Provost D; Cazes M; Caussade F; Cloarec A
    Br J Pharmacol; 1997 Feb; 120(3):488-94. PubMed ID: 9031754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.